Miruvor
Sign up
The short answer

What studies of cognitive rehabilitation found

31papers on cognitive rehabilitation
510people in 9 studies testing cognitive rehabilitation alone
4randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, the placebo trial and randomised trials (low certainty): 1 of 2 findings is B, a tie, so the grade of fatigue, as the rule below says.

8 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Cognitive rehabilitation may help for long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 31 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Cognitive rehabilitation · Long COVID is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue2 studies · 40 people took part in cognitive rehabilitation Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (72 in all); only people who finished were analysed.

Randomised trials2 studies · 72 people with results

Fatigue improved more than in the comparison group.

Cognitive rehabilitation may reduce fatigue in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (72 in all)
  • Only people who finished were analysed
See the 2 studies
  1. Long COVID Brain Fog Treatment: Findings from a Pilot Randomized Controlled Trial of Constraint-Induced Cognitive Therapy. (2024)

    People in the study
    16 randomised · 14 analysed
    Dose
    approximately 20%, each training session
    Outcome
    Fatigue Assessment Scale (FAS) Fatigue Assessment Scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial. (2026)

    People in the study
    58 randomised
    Dose
    90-minute CR intervention sessions, 12-week programme of 9 small group (3-5 participants) and 3 individual sessions
    Outcome
    PROMIS-29 fatigue short PROMIS-29 v4.0 fatigue short scale
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Cognition (brain fog)8 studies · 497 people took part in cognitive rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; randomised trials found little or no difference.

Randomised trials4 studies · 210 people with results

No clear difference in cognition (brain fog).

The evidence is very uncertain about the effect of cognitive rehabilitation on cognition (brain fog) in long COVID. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • 210 people in all; a small benefit can't be ruled out
  • Only people who finished were analysed
  • The studies disagree

Compared with another group, not randomised134 in the study · 123 with outcome data · 8 weeks · lasting 8 weeks

Cognition (brain fog) improved more than in the comparison group.

The evidence is very uncertain about the effect of cognitive rehabilitation on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance

Studies with no comparison group3 studies · 308 people with results

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of cognitive rehabilitation on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
  • The studies disagree

Combination: CBT and psychotherapy + Cognitive rehabilitation

Effects of cognitive training and group psychotherapy on cognitive performance of post COVID-19 patients: an exploratory and non-randomized clinical trial. (2024): Story Memory (SM), better.

Shown, not counted: cognitive rehabilitation was given together with other treatments.

See the 8 studies
  1. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial. (2026)

    People in the study
    58 randomised
    Dose
    90-minute CR intervention sessions, 12-week programme of 9 small group (3-5 participants) and 3 individual sessions
    Outcome
    HVLT-R, Recognition discrimination Hopkins Verbal Learning Test-Revised
    Effect
    worse
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial. (2026)

    People in the study
    78 randomised
    Dose
    10 individual 1-hour sessions, once per week
    Outcome
    D-KEFS Trail Making Condition 4, number-letter sequencing at 3 months Delis–Kaplan Executive Functioning System
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  3. Long COVID Brain Fog Treatment: Findings from a Pilot Randomized Controlled Trial of Constraint-Induced Cognitive Therapy. (2024)

    People in the study
    16 randomised · 14 analysed
    Dose
    approximately 20%, each training session
    Outcome
    Montreal Cognitive Assessment (MoCA) Montreal Cognitive Assessment
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  4. Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint

    People in the study
    60 randomised
    Dose
    nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
    Outcome
    N-back task performance (untrained working memory), primary outcome, CT vs PMR at post-intervention
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  5. Neuropsychological rehabilitation for post-COVID-19 syndrome: results of a clinical programme and six-month follow up. (2024)

    People in the study
    134 in the study · 123 with outcome data
    Dose
    lasting 8 weeks
    Outcome
    Effect size Rey Auditory Verbal Learning Test
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: control group selected by normal neuropsychological examination The remaining 26% (n = 32) presented normal results in the neuropsychological examination and therefore did not receive treatment for cognitive symptoms
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  6. LearningRx Cognitive Training for Workplace Self-Efficacy in Adults with Post-COVID-19 Brain Fog: A Mixed-Methods Pilot Study. (2026)

    People in the study
    11 in the study · 9 with outcome data
    Dose
    45 to 90 training hours, two or three 60–90 min training sessions per week
    Outcome
    Cognitive Performance Rating Workplace Self-Efficacy Survey (WSES)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  7. [Neuropsychological rehabilitation for post-COVID-19 syndrome: Results of a clinical program and six-month follow up.]. (2022)

    People in the study
    134 in the study · 123 with outcome data
    Dose
    una media de 4,1 sesiones semanales, sesiones terapéuticas —de una hora de duración—
    Outcome
    Orientación en persona Test Barcelona
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  8. Long COVID neuropsychological follow-up: Is cognitive rehabilitation relevant? (2023)

    People in the study
    208 with outcome data
    Dose
    —
    Outcome
    neuropsychological symptoms
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression3 studies · 53 people took part in cognitive rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all); only people who finished were analysed; the studies disagree; randomised trials found mixed results.

Randomised trials2 studies · 72 people with results

Studies disagree about depression.

Studies disagree about whether cognitive rehabilitation helps depression. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (72 in all)
  • Only people who finished were analysed
  • The studies disagree

Studies with no comparison group13 in the study · On admission and at discharge

Too little to say about depression.

Too little to say: depression got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 3 studies
  1. Long COVID Brain Fog Treatment: Findings from a Pilot Randomized Controlled Trial of Constraint-Induced Cognitive Therapy. (2024)

    People in the study
    16 randomised · 14 analysed
    Dose
    approximately 20%, each training session
    Outcome
    Patient Health Questionnaire-9 (PHQ-9) median scores Patient Health Questionnaire-9
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial. (2026)

    People in the study
    58 randomised
    Dose
    90-minute CR intervention sessions, 12-week programme of 9 small group (3-5 participants) and 3 individual sessions
    Outcome
    PHQ-8 Patient Health Questionnaire-8
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  3. Demographics, Clinical Characteristics, and Outcomes of a Post-Coronavirus-19 Sample After Cognitive Rehabilitation: A Case Series. (2025)

    People in the study
    13 in the study
    Dose
    —
    Outcome
    PHQ-9 change Patient Health Questionnaire (PHQ-9)
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Anxiety2 studies · 40 people took part in cognitive rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (72 in all); only people who finished were analysed; the studies disagree; randomised trials found mixed results.

Randomised trials2 studies · 72 people with results

Studies disagree about anxiety.

Studies disagree about whether cognitive rehabilitation helps anxiety. Mixed results · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (72 in all)
  • Only people who finished were analysed
  • The studies disagree
See the 2 studies
  1. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial. (2026)

    People in the study
    58 randomised
    Dose
    90-minute CR intervention sessions, 12-week programme of 9 small group (3-5 participants) and 3 individual sessions
    Outcome
    GAD-7 Generalized Anxiety Disorder-7
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  2. Long COVID Brain Fog Treatment: Findings from a Pilot Randomized Controlled Trial of Constraint-Induced Cognitive Therapy. (2024)

    People in the study
    16 randomised · 14 analysed
    Dose
    approximately 20%, each training session
    Outcome
    General Anxiety Disorder-7 (GAD-7) General Anxiety Disorder-7
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Low mood or anxiety2 studies · 182 people took part in cognitive rehabilitation Uncertain –
Very low certainty

Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; one study saw it get worse, without a test against chance.

Compared with another group, not randomised134 in the study · 123 with outcome data · 8 weeks · lasting 8 weeks

Too little to say about low mood or anxiety.

Too little to say: low mood or anxiety got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance

Studies with no comparison group134 in the study · 123 with outcome data · 8 semanas de duración · una media de 4,1 sesiones semanales, sesiones terapéuticas —de una hora de duración—

Low mood or anxiety improved.

The evidence is very uncertain about the effect of cognitive rehabilitation on low mood or anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. Neuropsychological rehabilitation for post-COVID-19 syndrome: results of a clinical programme and six-month follow up. (2024)

    People in the study
    134 in the study · 123 with outcome data
    Dose
    lasting 8 weeks
    Outcome
    Effect size Hospital Anxiety and Depression Scale
    Effect
    worse (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: control group selected by normal neuropsychological examination The remaining 26% (n = 32) presented normal results in the neuropsychological examination and therefore did not receive treatment for cognitive symptoms
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. [Neuropsychological rehabilitation for post-COVID-19 syndrome: Results of a clinical program and six-month follow up.]. (2022)

    People in the study
    134 in the study · 123 with outcome data
    Dose
    una media de 4,1 sesiones semanales, sesiones terapéuticas —de una hora de duración—
    Outcome
    HADS-Ansiedad Escala de Ansiedad y Depresión Hospitalaria (Hospital Anxiety and Depression Scale [HADS])
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning6 studies · 120 people took part in cognitive rehabilitation Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from randomised trials: some concerns about bias (RoB 2); few people (210 in all); the studies disagree; randomised trials found mixed results.

Randomised trials4 studies · 210 people with results

Studies disagree about daily functioning.

Studies disagree about whether cognitive rehabilitation helps daily functioning. Mixed results · very low certainty C

  • Some concerns about bias (RoB 2)
  • Few people (210 in all)
  • The studies disagree

Studies with no comparison group2 studies · 22 people with results

Daily functioning improved.

The evidence is very uncertain about the effect of cognitive rehabilitation on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (22 in all)
  • Not all results were tested against chance
See the 6 studies
  1. Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial. (2026)

    People in the study
    78 randomised
    Dose
    10 individual 1-hour sessions, once per week
    Outcome
    Goal attainment (BGSI) at 3 months Bangor Goal-Setting Interview
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Low
  2. Long COVID Brain Fog Treatment: Findings from a Pilot Randomized Controlled Trial of Constraint-Induced Cognitive Therapy. (2024)

    People in the study
    16 randomised · 14 analysed
    Dose
    approximately 20%, each training session
    Outcome
    COPM Performance scale Canadian Occupational Performance Measure
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Low
  3. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial. (2026)

    People in the study
    58 randomised
    Dose
    90-minute CR intervention sessions, 12-week programme of 9 small group (3-5 participants) and 3 individual sessions
    Outcome
    FAQ R Functional Activities Questionnaire
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
  4. Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint

    People in the study
    60 randomised
    Dose
    nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
    Outcome
    Functional status (Post-COVID Functional Status Scale), CT vs PMR Post-COVID Functional Status Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  5. LearningRx Cognitive Training for Workplace Self-Efficacy in Adults with Post-COVID-19 Brain Fog: A Mixed-Methods Pilot Study. (2026)

    People in the study
    11 in the study · 9 with outcome data
    Dose
    45 to 90 training hours, two or three 60–90 min training sessions per week
    Outcome
    Workplace Self-Efficacy Score Workplace Self-Efficacy Survey (WSES)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  6. Demographics, Clinical Characteristics, and Outcomes of a Post-Coronavirus-19 Sample After Cognitive Rehabilitation: A Case Series. (2025)

    People in the study
    13 in the study
    Dose
    —
    Outcome
    M2PI T-score change Participation Index of the Mayo-Portland Adaptability Inventory Participation Index (M2PI)
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life2 studies · 33 people took part in cognitive rehabilitation Little or no difference D
Low certainty

Why this grade: Little or no difference, low certainty, from randomised trials: one trial of 60 people found no clear difference; a small benefit can't be ruled out.

The placebo trial60 randomised · nine 20-minute intervention sessions over three weeks · nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday

No clear difference in quality of life.

Cognitive rehabilitation may make little or no difference to quality of life in long COVID. Little or no difference · low certainty D

  • One trial of 60 people found no clear difference; a small benefit can't be ruled out

Studies with no comparison group13 in the study · On admission and at discharge

Too little to say about quality of life.

Too little to say: quality of life got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
  • Not all results were tested against chance
  • One study saw it get worse, without a test against chance
See the 2 studies
  1. Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial (2026) preprint

    People in the study
    60 randomised
    Dose
    nine 20-minute intervention sessions over three weeks, three sessions per week on alternating days: Monday, Wednesday, and Friday
    Outcome
    Health-related quality of life (PROPr score), CT vs PMR PROMIS-Preference (PROPr) score
    Effect
    no clear difference
    Risk of bias
    RoB 2: Low
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Low
  2. Demographics, Clinical Characteristics, and Outcomes of a Post-Coronavirus-19 Sample After Cognitive Rehabilitation: A Case Series. (2025)

    People in the study
    13 in the study
    Dose
    —
    Outcome
    SWLS change Satisfaction with Life Scale (SWLS)
    Effect
    worse (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 13 people took part in cognitive rehabilitation Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all).

Studies with no comparison group13 in the study · On admission and at discharge

No clear change in overall symptoms.

The evidence is very uncertain about the effect of cognitive rehabilitation on overall symptoms in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (13 in all)
See the 1 study
  1. Demographics, Clinical Characteristics, and Outcomes of a Post-Coronavirus-19 Sample After Cognitive Rehabilitation: A Case Series. (2025)

    People in the study
    13 in the study
    Dose
    —
    Outcome
    overall outcome measures
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of cognitive rehabilitation given together with other treatments looked at. Shown, not graded: they can’t tell what cognitive rehabilitation did alone.

Cognition (brain fog) Both together

Combination: Phosphatidylcholine + Cognitive rehabilitation29 randomised

Exploring cognitive impairments and the efficacy of phosphatidylcholine and computer-assisted cognitive training in post-acute COVID-19 and post-acute COVID-19 Vaccination Syndrome. (2024): Cognitive performance, no clear difference.

Shown, not counted: cognitive rehabilitation was given together with other treatments.

Side effects

Stopping because of side effects4 studies
Side effects studies reported1 kind
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Worse symptoms or a flare1 study

All papers

  1. Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.2026 · randomised trial · 328 randomised · 320 started
    Summary

    This 5-arm, multicenter randomized trial asked whether remotely delivered rehabilitation strategies improve cognitive symptoms in people with cognitive long COVID. It enrolled 328 participants at 22 trial sites in the US; 320 received at least 1 intervention. Over 10 weeks, participants were assigned to adaptive online BrainHQ, PASC-CoRE (9 90-minute group sessions and 3 30-minute individual sessions) plus BrainHQ, active tDCS (2.0 mA for 30 minutes) plus BrainHQ, an active comparator of online puzzles and games, or sham tDCS plus BrainHQ, with interventions 5 times per week. The primary outcome was the modified ECog2 at the end of intervention. There were no differences on the modified ECog2 for any prespecified primary treatment comparison in the ITT population (N = 328); adjusted differences were 0.0 (95% CI, −0.2 to 0.2) for BrainHQ vs active comparator, 0.1 (−0.1 to 0.3) for PASC-CoRE + BrainHQ vs active comparator, 0.0 (−0.2 to 0.2) for tDCS-active + BrainHQ vs tDCS-sham + BrainHQ, and 0.1 (−0.1 to 0.3) for PASC-CoRE + BrainHQ vs BrainHQ alone. At EOI, the modified ECog2 improved in the range of approximately half an SD in all study arms; secondary outcomes showed no differential benefits. On the overall-functioning item, 4/300 (1.3%) reported much worse and 16/300 (5.3%) somewhat worse; 222/299 (74.2%) said the intervention helped cognitive functioning. At EOI, 143 participants (56%) reported postexertional malaise; no participants discontinued prematurely due to postexertional malaise. In the modified ITT population (n = 320), 11 participants experienced treatment-emergent serious adverse events; there were no serious adverse events attributable to the interventions, and one participant receiving active tDCS reported a minor thermal injury. Limitations included uncertainties about the pathobiology and possible unexpected therapeutic benefits from the active comparator.

  2. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial.2026 · randomised trial · 58 randomised
    Summary

    Fifty-eight people with long COVID and cognitive impairment were recruited from the Mount Sinai Health System in New York City and randomised to 29 per arm. One arm received a virtual 12-week cognitive rehabilitation programme of 9 small-group and 3 individual sessions plus BrainHQ homework; the other received a time- and attention-matched control programme with a brain health didactic and online puzzles. Cognitive functioning was assessed at baseline and within 2-weeks post-intervention. The paper reports that none of the objective cognitive changes differed significantly between groups, and that the analyses did not show futility for any cognitive measure except attention, working memory and novel problem-solving. The intervention group self-reported significant improvement in cognitive functioning on the Cognitive Failures Questionnaire compared with controls. Anxiety and fatigue also improved significantly in the intervention group compared with controls, while no significant improvement was found for depression or daily functioning. Overall, 88% of participants completed the intervention. The authors state that limitations include a small sample size and relatively high rates of self-reported depression and anxiety at baseline.

  3. Resting-State Functional Connectivity and Cognitive Performance in Long COVID: A Randomized Controlled Trial2026 · randomised trial · 58 randomised · 39 analysed · preprint
    Summary

    This preprint reports a neuroimaging analysis of a parallel-group randomized controlled trial of cognitive rehabilitation for adults with long COVID and objectively confirmed mild-to-moderate cognitive impairment. Participants were recruited from the Mount Sinai Health System (New York City) between September 2022 and August 2024. Fifty-eight participants were randomized; 39 completed both imaging sessions (19 in the intervention group and 20 in the control group). The 12-week intervention combined virtual cognitive rehabilitation and small-group and individual sessions with computerized cognitive training, and was compared with an attention-matched control condition. Cognitive testing and resting-state functional MRI were done at baseline and within two weeks post-intervention. The imaging analysis examined connectivity within and between the central executive, salience and default mode networks. No significant effects of timepoint, intervention or their interaction were found on overall network connectivity (intervention b = -0.011, p = 0.11; interaction b = 0.003, p = 0.66), within the canonical networks (all p-values > 0.25), or between network pairs. No adverse events related to the intervention or imaging procedures were reported during the study period. The authors state the pilot was not powered to detect small-to-moderate effects on resting-state connectivity and describe the findings as preliminary.

  4. Long COVID Brain Fog Treatment: Findings from a Pilot Randomized Controlled Trial of Constraint-Induced Cognitive Therapy.2024 · randomised trial · 16 randomised · 14 analysed
    Summary

    Long COVID brain fog is often disabling, and the authors state no empirically supported treatments exist. In this pilot RCT, 16 community residents at least 3 months after COVID-19 with mild cognitive impairment and dysfunction in instrumental activities of daily living were enrolled from a University of Alabama at Birmingham post-COVID clinic, plus a few after press reports. Participants received Immediate-CICT or treatment-as-usual (TAU), with TAU crossing over to CICT. CICT combined Speed of Processing Training, in-lab IADL training, and the Transfer Package; 36 hours were scheduled over 2 to 7 weeks. Fourteen completed Immediate-CICT (n=7) or TAU (n=7); two withdrew from TAU before their second testing session, and three additional TAU participants dropped before crossover because of medical problems (n=2) or loss of interest (n=1). Immediate-CICT, compared with TAU, showed improvements on COPM Performance (MD=3.7 points, 95% CI 2.5–4.9, p<.001), brain fog on the MCS (MD=−4 points, 95% CI −5.3 to −2.6, p<0.001), fatigue on the FAS (MD=−10.9 points, 95% CI −17.4 to −4.4, p=0.02), and return-to-work (four of five vs none; p=0.048). Depressive symptoms and SDMT processing speed also favored Immediate-CICT; anxiety was not statistically significant (p=0.09), and no advantage was seen on MoCA (MD=0.7 points, p=0.73). The text reports no study-related adverse events.

  5. Neuropsychological rehabilitation for post-COVID-19 syndrome: results of a clinical programme and six-month follow up.2024 · compared with another group · 134 in the study · 123 with outcome data
    Summary

    Between June 2020 and September 2021, 134 patients with post–COVID-19 syndrome participated in an Institut Guttmann outpatient neurorehabilitation programme; 123 met inclusion criteria and were analysed. Of these, 91 patients with cognitive impairment received cognitive treatment (study group) and 32 with normal neuropsychological examination did not (control group). The programme lasted 8 weeks and included respiratory therapy, physiotherapy and neuropsychological rehabilitation; patients completed a mean of 4.1 sessions of cognitive treatment per week. The study group improved from pre- to post-treatment in forward digit span, backward digit span, RAVLT-learning, RAVLT-recall, RAVLT-recognition, verbal fluency, HADS-anxiety and HADS-depression. The control group changed in forward digit span, RAVLT-learning, RAVLT-recognition and HADS-depression. The study group presented larger effect sizes for backward digit span (0.30 vs 0.07), RAVLT-learning (0.51 vs 0.30), RAVLT-recall (0.51 vs 0.16), RAVLT-recognition (0.38 vs 0.27), verbal fluency (0.48 vs 0.19), HADS-anxiety (0.28 vs 0.19) and HADS-depression (0.32 vs 0.26); the control group only had a larger effect size for forward digit span (0.22 vs 0.28). The paper reports no intergroup differences at post-treatment or follow-up. At follow-up, the study group was poorer than post-treatment for forward digit span and RAVLT-recognition; the control group showed no differences between post-treatment and follow-up. At follow-up, 33.3% (n = 23) had returned to work, 44.9% (n = 31) were temporarily unable to work, and 81.2% (n = 56) reported difficulties in activities of daily living. Harms and withdrawals for harms were not reported.

  6. Effects of Multidisciplinary Rehabilitation Enhanced with Neuropsychological Treatment on Post-Acute SARS-CoV-2 Cognitive Impairment (Brain Fog): An Observational Study.2023 · compared with another group · 64 in the study
    Summary

    This prospective monocentric observational registry enrolled 64 consecutive adults with post-acute COVID-19 syndrome after moderate-to-severe COVID-19 requiring hospitalization, admitted to an inpatient rehabilitation unit in Parma, Italy. Of these, 56 had brain fog. Patients with cognitive impairment (MoCA <26) received a day-by-day individualized psychological intervention of cognitive stimulation (45 min) on top of a standard in-hospital rehabilitation program; the program lasted 30 ± 10 days. Patients with normal MoCA at admission underwent only the standard rehabilitation program. Cognitive function was measured with the Montreal Cognitive Assessment (MoCA), plus HADS-A, HADS-D, EQoL, IES-R and Barthel index. Mean MoCA improved from 20.4 ± 5 to 24.7 ± 3.7 (p < 0.0001). In treated patients, MoCA improved from 19.5 ± 4.6 to 24.2 ± 3.7 (p < 0.0001); in untreated patients with normal MoCA at admission, change was 27 ± 0.9 to 28 ± 1.7 (p = 0.138). At admission, 12.5% had no cognitive impairment, 56.3% mild, 28.1% moderate, 3.1% severe; at discharge 50% were normal, 45.3% mild, 4.7% moderate, none severe. No patient showed worsening of cognitive impairment. No significant improvement was found in HADS-A, HADS-D, EQoL, or IES-R; Barthel index improved (p < 0.0001), with no correlation between MoCA and Barthel change (r = 0.085; p = 0.417). The program was well tolerated and did not worsen psychological parameters. Withdrawals due to harms were not reported. Limitations stated were small sample size (64 patients), lack of a control group, and a few patients with previous neurological diseases.

  7. [Neuropsychological rehabilitation for post-COVID-19 syndrome: Results of a clinical program and six-month follow up.].2022 · compared with another group · 134 in the study · 123 with outcome data
  8. LearningRx Cognitive Training for Workplace Self-Efficacy in Adults with Post-COVID-19 Brain Fog: A Mixed-Methods Pilot Study.2026 · no comparison group · 11 in the study · 9 with outcome data
    Summary

    This prospective, single-arm pilot study asked whether Brain Strong (formerly Brain Booster), a clinician-delivered cognitive training programme, was associated with changes in workplace self-efficacy and cognition in adults with post-COVID-19 brain fog. Eleven participants enrolled from across the United States; two withdrew early due to unanticipated family needs, and nine were included in the final analytic sample. Training was delivered remotely over Zoom for 45 to 90 training hours, in two or three 60–90 min sessions per week, with a reported total training period of 4 to 13 months (the discussion states 5 to 15 months). There was no control group. The primary measure was a Workplace Self-Efficacy Survey plus interviews; the secondary measure was the Woodcock Johnson IV General Intellectual Ability score. On the survey, overall workplace self-efficacy rose from a mean of 119.66 after COVID-19 to 201.22 after training (p = 0.003); work performance rose from 90.89 to 148.11 (p = 0.003), and cognitive performance from 28.78 to 53.11 (p = 0.006). The three home-functioning items changed across timepoints (p < 0.001). Eight participants completed interviews and cognitive assessments; the mean IQ change was 10.5 points, from 99.5 to 110.0 (p < 0.001). No side effects were reported. The authors state limitations including the nine-participant sample, no control group, possible practice effects, and retrospective baseline reporting.

  9. Long COVID neuropsychological follow-up: Is cognitive rehabilitation relevant?2023 · no comparison group · 208 with outcome data
    Summary

    This follow-up study examined 208 patients with long COVID (mean age of 48.8 y.o., mostly female) who were reevaluated 25 months after their first COVID infection and 17 months after their initial evaluation. The treatment recorded was psychoeducational neuropsychological rehabilitation; treatment duration and setting were not reported. There was no comparison group. Assessments included subjective assessment, the Barrow Neurological Institute Screen for Higher Cerebral Functions (BNIS), Phonemic Verbal Fluency and Clock Drawing Tests (NEUPSILIN) for executive functions, the Hospital Anxiety and Depression Scale (HADS), and WHOQol-Bref. The abstract reports a discrete improvement of neuropsychological symptoms 25 months after the acute stage of COVID-19, but performance was not within the normative parameters of standardized neuropsychological testing. Improvement was seen in those who participated in psychoeducational neuropsychological rehabilitation, had higher levels of education, and lower depression scores on the HADS. Harms and withdrawals were not reported. The authors conclude that long-term cognitive and neuropsychiatric disorders persist and that neuropsychological rehabilitation is shown to be important, whether in-person or online.

  10. Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings.2026 · case report · 1 in the study
    Summary

    This case report describes one patient with highly symptomatic post-COVID-19 condition (also known as long COVID). The setting was not reported. High-dose intravenous immunoglobulin therapy was given at 400 mg/kg per day for 5 consecutive days. After 4 weeks, a maintenance dose of 500 mg/kg was given for 1 day, followed by two further maintenance cycles of 500 mg/kg per day for 3 consecutive days, each at 4-week intervals. In parallel, the patient underwent a cognitive stimulation intervention. There was no comparison group and no randomisation. Neurological symptoms were assessed with the Fatigue Assessment Scale and the WHO Disability Assessment Schedule 2.0; neurocognitive performance, quality of life, and the immunological profile were also followed longitudinally. Fatigue scores normalised, neurocognitive performance returned to normal value, and quality of life improved after the first infusion and fully recovered within 1 year. The authors report sustained clinical recovery from long COVID over 1 year of follow-up, accompanied by immunological changes consistent with modulation of post-viral immune dysregulation. Side effects and withdrawals were not reported. The authors state that causal inference cannot be established from a single patient.

  11. Demographics, Clinical Characteristics, and Outcomes of a Post-Coronavirus-19 Sample After Cognitive Rehabilitation: A Case Series.2025 · case report · 13 in the study
    Summary

    This case series examined 13 post-COVID-19 patients with PASC who were referred to the Brain Rehabilitation Clinic through the COVID-19 Activity Rehabilitation Program and underwent individualized multidisciplinary outpatient cognitive rehabilitation. The median age was 46 years, 77% were women, and 85% were White; median time from infection to treatment was 229 days and median length of stay in the program was 4.9 months. Treatment included cognitive rehabilitation and CBT, with 60-minute sessions and no target number of sessions or length of overall treatment. There was no comparison group; outcomes were measured on admission and at discharge with the M2PI, SWLS, PHQ-9, and NSI-22. All 13 completed the program. Median changes were −4 on the M2PI, −2 on the SWLS, 1 on the PHQ-9, and −2 on the NSI-22. The abstract states no clear benefit was seen in any outcome measure, and the results state overall there were very minimal changes across all outcome measures. Worsening scores occurred in 3 of 13 patients on the M2PI and 7 of 13 on the NSI-22; 5 of 13 had positive SWLS scores and 5 of 13 had negative PHQ-9 scores. No observed associations were found between time to treatment, length of stay, number of visits, and changes in these measures. Limitations include a small cohort of a unique subset, no formal statistical testing, and individualized care without a target number of sessions or length.

  12. Exploring cognitive impairments and the efficacy of phosphatidylcholine and computer-assisted cognitive training in post-acute COVID-19 and post-acute COVID-19 Vaccination Syndrome.2024 · combination: given with other treatments · 29 randomised
    Summary

    Researchers at the Neuro-COVID Outpatient Clinic, Evangelic Hospital Vienna, conducted a prospective study to understand cognitive deficits and evaluate phosphatidylcholine and computer-assisted cognitive training (CCT) in post-acute COVID-19 syndrome (PACS) and post-acute COVID-19 vaccination syndrome (PACVS). They enrolled 29 patients (25 with PACS and 4 with PACVS). Group A (n=9) received 22.5 mL liquid phosphatidylcholine three times daily for 4 weeks; group B (n=10) received the same phosphatidylcholine plus access to the myReha app for 4 weeks with a minimum daily training duration of 25 min (Monday to Friday); group C1 (n=5) and C2 (n=5) first received no therapy for 4 weeks, then the group A or B treatments. Cognitive performance was measured with COGBAT and quality of life with WHOQOL-BREF. COGBAT cognitive performance improved significantly in group A (p=0.011), group B (p=0.031), and group C1 (p=0.009 first to second, p=0.037 second to third, p<0.001 first to third); group C2 showed a positive trend (p=0.053, p=0.090, p=0.058). There was no significant interaction between assessment time and treatment scheme for cognitive performance (p=0.714), attention (p=0.438), memory (p=0.493), or executive functions (p=0.775). Subjectively, 14 patients (48.3%) reported cognitive improvement; by scheme, 33.3% in A, 40.0% in B, 60.0% in C1, and 80.0% in C2. WHOQOL-BREF physical health improved in group A (p=0.032); other WHOQOL domains mostly showed no significant progress, except environment in C1 (p=0.041). Side effects and withdrawals were not reported. The authors state the study was not double-blinded, had a low sample size, and an 8-week follow-up may be insufficient.

  13. Effects of cognitive training and group psychotherapy on cognitive performance of post COVID-19 patients: an exploratory and non-randomized clinical trial.2024 · combination: given with other treatments
    Summary

    This exploratory, non-randomized, non-blinded controlled clinical trial enrolled Post COVID-19 (PC) patients at the Post-COVIDLMU outpatient clinic. A total of 19 PC patients started the intervention group; 15 completed it. The intervention was a weekly group of cognitive training and group psychotherapy for 8 weeks: the first session was 90 min of group psychotherapy, and subsequent sessions were 45 min of group psychotherapy followed by 45 min of cognitive training. A control group of 15 PC patients did not participate in the intervention and underwent two cognitive assessments. Cognitive performance was assessed before and after intervention group participation; the interval was 113.87 days on average in the intervention group and 121.53 days in the control group. Within the intervention group, significant improvements were found for most cognitive measures. Significant time x group interactions were only detected in some dimensions of verbal memory and visuo-spatial construction skills; there was no significant interaction effect in the other 16 variables. Significant time effects were observed for attention, concentration, memory, executive functions, and processing speed. BDI-II depressive symptomatology decreased significantly in the intervention group (p = .004). In the intervention group, 96% found the group helpful, 92% found the topics relevant, 88% were satisfied with the course, and 76% could implement the content in daily lives. On average each patient participated in 5 to 6 of 8 therapy sessions, and six of 15 completed all 8 sessions. Four intervention participants dropped out, one due to deterioration of his physical condition; patients also reported burden of the journey and subjective exhaustiveness. The authors state limitations of small sample size and non-randomized design.

  14. Persistent Cognitive Dysfunction in a Non-Hospitalized COVID-19 Long-Hauler Patient Responding to Cognitive Rehabilitation and Citicoline Treatment.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case report describes one non-hospitalized 59-year-old woman who developed forgetfulness and anomia after a mild SARS-CoV-2 infection and was diagnosed with Post COVID-19 Neurological Syndrome at the Memory Clinic of the University Hospital of Palermo. She received oral citicoline 1000 mg/daily and cognitive rehabilitation (two 40 min sessions per week) for six months. There was no comparison group; outcomes were reported before versus after treatment. Neuropsychological testing, anxiety and depression scales, and a subjective memory questionnaire were administered. After six months, the paper reports a marked improvement in symptoms, an overall improvement in cognitive performance, a reduction in anxiety levels, and reduced subjective reporting of memory deficits. At follow-up the patient had normal scores in all cognitive tests, with borderline delayed recall on the RAVLT. Harms and withdrawals were not reported. The authors did not report randomisation, blinding, or a control group.

  15. Teleintervention for Persisting Symptoms Post-Acute COVID-19 Illness Using Transcranial Direct Current Stimulation (tDCS) (P18-6.001)2022 · combination: given with other treatments · 2 in the study · abstract
    Summary

    Two women aged 42 and 57 with Post-Acute Sequelae of SARS-CoV-2 (PASC), seen 7 and 9 months after acute COVID-19 illness at a clinical transcranial direct current stimulation (tDCS) telehealth service at NYU Langone Health, received daily at-home tDCS sessions delivered via video visit for 30 minutes x 2.0 mA using a left anodal dorsolateral prefrontal cortex montage. Stimulation was paired with physical exercise, online adaptive computerized cognitive training, and guided mindfulness meditation, individualized to each patient, with sessions 3–5 days per week. There was no comparison group; clinical neuropsychological evaluation was completed before and after the intervention, and a symptom inventory based on the full range of PASC symptoms reported in the literature (Assessment of PASC; A-PASC) was developed to measure treatment outcomes. The paper reports that the patients experienced significant improvements across cognitive, emotional, physical, and functional domains, and both returned to work and resumed most of their daily activities following the intervention. Harms, side effects, and withdrawals were not reported. The authors state that tDCS can be delivered as a teleintervention warranting its evaluation as an accessible and scalable treatment option for PASC, and that further study and clinical trials of PASC are warranted. No formal limitations section is stated.

  16. The Effectiveness of Non-Pharmacological Interventions in Treating Adolescents and Young Adults with Neuropsychiatric Symptoms of Long COVID: A Systematic Review and Meta-Analysis.2026 · systematic review
    Summary

    This systematic review and meta-analysis examined non-pharmacological interventions for neuropsychiatric symptoms of long COVID in adolescents and young adults aged 13–25 years. The review included seven studies; the recorded sample sizes were 17, 16, 208, 124, 22, 239, and 36 participants. Interventions included forest bathing, TTM, a neuropsychological rehabilitation program, a multidisciplinary post-COVID rehabilitation program, micro-choice based concentrated group rehabilitation, and EECP. Durations varied, and the review reported that most studies lacked a comparison group. Outcomes included mental health, anxiety, depression, fatigue, QoL, cognitive function, headaches, and insomnia. In the meta-analysis, the pooled mental health result was statistically significant (SMD 0.64, 95% CI 0.0012 to 1.2692, p<0.0497). Pooled results for fatigue (SMD 1.74, 95% CI −0.9416 to 4.4262, p=0.1307), QoL (SMD −1.34, 95% CI −5.2620 to 2.5784, p=0.2787), and cognitive function (SMD 1.05, 95% CI −2.1961 to 4.2934, p=0.2989) were not statistically significant. Individual studies reported improvements in several outcomes; Chokpaisam et al reported no statistically significant change in emotional well-being (78.35 ± 17.44 vs 81.18 ± 17.99, p=0.336), and Kvale et al reported no statistically significant difference in anxiety and depression (27.3% vs 38.2%, p=0.210). No harms or withdrawals were recorded. The authors stated limitations including cohort designs without comparison groups, no age-based subgroup analyses, small sample sizes, and heterogeneity.

  17. PSYCHONEUROLOGICAL THERAPY FOR POST-COVID SYNDROME: A COMPREHENSIVE REVIEW OF METHODS AND CLINICAL EFFECTIVENESS.2026 · systematic review
    Summary

    Review of psychoneurological therapies for post-COVID syndrome in adults with persistent cognitive, emotional or neurological symptoms. No new participants were enrolled; eligible randomized controlled trials, observational studies and clinical reports published up to 2024 were summarized narratively. The review describes SSRIs, SNRIs, anxiolytics, antipsychotics, nootropics, CBT and psychodynamic therapy, mindfulness, physiotherapy and exercise, breathing, massage, acupuncture, social rehabilitation, TMS and ECT. It reports that in a randomized clinical trial (2021), SSRIs reduced depression and anxiety in 150 PCS patients, with 60% improving on the Hamilton scale after 12 weeks; venlafaxine improved cognitive function and reduced anxiety in 80 patients compared with placebo. CBT produced marked improvement in 65% after 8 weeks, and a 60% reduction in post-traumatic symptoms was observed in another CBT study. Acupuncture was followed by substantial improvement in 65%, social rehabilitation helped 75% regain social and occupational abilities, and physiotherapy improved endurance and reduced chronic fatigue in 80%. Harms mentioned include risk of dependence with benzodiazepines, mild headaches or localized discomfort with TMS, and short-term memory loss or cognitive disturbances with ECT. The authors state that individualized, combined strategies are most effective; they note that each strategy has limitations and requires further research.

  18. Cognitive Interventions and Rehabilitation to Address Long-COVID Symptoms: A Systematic Review.2026 · systematic review
    Summary

    This systematic review examined cognitive interventions and rehabilitation for adults with long COVID symptoms. It included 19 articles identified from MEDLINE, CINAHL, PsycINFO, Cochrane Trials, and Scopus, with a search date of July 25, 2023. The review summarized cognitive training, CBT, neurostimulation, combined neurostimulation and cognitive training, and multicomponent rehabilitation programs. Included studies had different designs; the review itself had no comparison group. In a 100-participant randomized trial, an amygdala and insula retraining program was reported to decrease fatigue and increase energy versus control. A 114-participant randomized trial reported CBT reduced fatigue versus care as usual and favored CBT on secondary measures. A 73-participant pre-post study reported higher cognitive scores in all assessed domains after computerized cognitive training. A 64-participant pre-post program reported 42.8% complete recovery and 68% varying improvement in cognitive function, plus significant improvement on the Barthel Index. A 33-participant program reported improved mood, self-efficacy, and participation but no significant fatigue improvement. A 12-participant program reported that all 12 gained insight and 11 reported increased work-life coping. One case report reported short-term memory decreased 15% to 22%. Stopping and side effects were not reported.

  19. Cognitive and Psychological Symptoms in Post-COVID-19 Condition: A Systematic Review of Structural and Functional Neuroimaging, Neurophysiology, and Intervention Studies.2025 · systematic review
    Summary

    This systematic review asked whether post-COVID-19 condition (PCC) is associated with structural, functional, and neurophysiological brain changes and evaluated noninvasive brain stimulation (NIBS) and cognitive rehabilitation. It included 78 studies with over 5927 individuals, searched in Web of Science, PubMed, and Embase. Treatments were NIBS, including TMS and tDCS, and cognitive rehabilitation/training; comparisons included active versus sham tDCS and rehabilitation versus no rehabilitation. Outcomes covered cognitive and psychological symptoms, fatigue, quality of life, and cognitive test performance. In a randomized tDCS study, 47 participants with PCC were randomized into active (n=23) and sham (n=24) groups; active tDCS significantly reduced physical fatigue immediately posttreatment and at 1-month follow-up and improved depressive symptoms, but no significant effects were seen for cognitive fatigue or overall quality of life. A 4-week randomized trial found a general reduction in fatigue severity over time across both groups, with within-group improvements significant only in the sham condition; no significant between-group differences were observed for fatigue domains, post-COVID symptom burden, anxiety and depressive symptoms, or cognitive function. Mild to moderate side effects such as tingling or burning sensations were reported in both groups and subsided; no persistent adverse effects were noted at follow-up. Cognitive training with tDCS showed greater improvements in cognitive and psychosocial fatigue, anxiety, and quality of life. Dual-task augmented reality rehabilitation improved cognitive performance in 10 participants compared with 10 who did not receive rehabilitation, with no significant differences for fatigue severity, cardiovascular endurance, or muscular fatigue. TMS studies reported improvements in depression, insomnia, anxiety, neuropsychiatric symptoms, apathy, and fatigue, while a double-blind trial found no significant changes in cognitive test outcomes. Stopping or worsening was not reported. The authors state limitations include heterogeneity and small numbers of high-quality randomized controlled trials.

  20. Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.2025 · systematic review
    Summary

    This systematic review asked whether non-invasive or minimally invasive brain stimulation reduces symptoms of post-COVID-19 condition. Four databases were searched through April 2nd, 2024; 19 studies were included, covering tDCS, TMS, tVNS and toACS. Across the included studies, Klirová et al. (33 patients) found no significant intergroup difference in post-COVID-19 symptoms. Santana et al. (70 patients) reported a significant reduction in fatigue and anxiety and an improvement in quality of life with active HD-tDCS compared with sham. Oliver-Mas et al. (47 patients) reported a significant improvement of physical fatigue and depressive symptoms in the active tDCS group compared with sham. Gracia et al. (15 patients) found no significant improvement across groups. Vestito et al. (7 patients) reported a significant improvement of hyposmia comparing tDCS with sham. Sakib et al. (4 patients) detected no significant group differences for rTMS. Badran et al. (13 patients) reported a trend towards mild to moderate effects of tVNS on fatigue. Reported harms included transient burning or tingling during tDCS, mild and transient headache and dizziness, transient tingling on the scalp, transient mild skin irritation with tVNS, and transient pain at the TMS stimulation site. The authors state that sample sizes are small, many studies are case reports, randomization and control groups are often missing, and diagnostic criteria differ.

  21. Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
    Summary

    This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.

  22. Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.2024 · systematic review
    Summary

    This qualitative systematic review asked which treatments have been studied for cognitive impairment after COVID-19. The search covered PubMed, Scopus, and ProQuest up to December 31, 2023, and included 29 studies of post-COVID cognitive impairment; samples ranged from single patients to larger groups. Treatments included cognitive remediation, multidisciplinary rehabilitation, noninvasive brain stimulation, hyperbaric oxygen, pharmacological and nutraceutical agents, neurofeedback, photobiomodulation, and meditation. Comparisons, where reported, included control, sham, placebo, or usual-care groups. Cognitive functioning was assessed with standardized tests, test batteries, or structured interviews. Findings varied. A randomized sham-controlled HBOT trial in 37 subjects reported significant improvements in global cognitive functioning, attention, and executive functions versus control. A famotidine RCT reported significantly improved global cognition in the treatment group (N = 25). A donepezil RCT found no differences between N = 15 and N = 10 in memory after 4 and 12 weeks. A tDCS randomized sham-controlled trial in 23 subjects found no significant effects on executive functioning and processing speed after eight tDCS sessions. A remote multidisciplinary RCT found no significant differences between N = 52 and N = 48. A multidisciplinary study in 80 subjects found no significant improvements in memory and attention at discharge. Other studies reported improvements in smaller or uncontrolled samples. No worsening, stopping, or side effects were reported in the recorded data. The authors state limitations including heterogeneity, lack of long-term follow-up, and under-characterization of samples.

  23. Intervention modalities for brain fog caused by long-COVID: systematic review of the literature.2024 · systematic review
    Summary

    This systematic review examined interventions for brain fog caused by long-COVID in adults with proven symptoms. It included 17 studies, including a case report of 1 patient and a cohort of 208. Interventions were rehabilitation (cognitive training, telerehabilitation, mindfulness-based programs), noninvasive brain stimulation (transcranial magnetic, direct current, alternating current stimulation, photobiomodulation), hyperbaric oxygen therapy, and PEA-LUT. Treatment duration varied; PEA-LUT was assessed three months after treatment. Some studies compared an intervention with control or treatment as usual, while others reported before-and-after changes. Outcomes included MoCA, MMSE, WAIS4, BNIS, NeuroTrax, CANTAB, TAP/AVLT, CAB, PEBL, and PDQ-D-5. Noninvasive brain stimulation studies all showed improvement in cognitive ability. Hyperbaric oxygen studies showed improvements in cognitive tests and brain perfusion. PEA-LUT improved PRMQ and MoCA scores in treated patients; in one trial mental clouding fell in groups 1 and 3 but not group 2. Rehabilitation results were mixed, with some studies reporting enhancement and others no significant improvement. Adverse effects were mild: scalp pain in 4 out of 23 patients after stimulation; after hyperbaric oxygen, barotrauma n=4, ear pain n=1, palpitations n=3, headache n=1, fever n=1. Rehabilitation and pharmacological treatment had no adverse effects. The authors state limitations include a limited number of studies and high heterogeneity.

  24. Resveratrol for Post-COVID-19 Cognitive Dysfunction: From Molecular Basis to Clinical Translation.2026 · review
    Summary

    This paper is a focused narrative review, not a clinical trial. The authors searched PubMed, Scopus and Web of Science through to May 2026 for evidence on whether resveratrol could treat post-COVID-19 cognitive dysfunction, described as brain fog. No participants were enrolled or treated in this work, and the authors state that "no randomized trial has tested its cognitive benefit in the intended population." The review describes other studies, including a 52-week randomized placebo-controlled trial in 119 participants with mild-to-moderate Alzheimer's disease, where dosing escalated from 500 mg once daily to 1000 mg twice daily, resveratrol and its metabolites were measurable in plasma and CSF, and nausea, diarrhea and weight loss were the most frequent adverse events. In acute COVID-19, a phase 2 outpatient trial in 100 evaluable participants reported hospitalization in 2% and 6%, emergency-department visits in 8% and 14%, and pneumonia in 8% and 16%, with "No clinically significant adverse event was attributed to resveratrol." A 24-month crossover trial in 125 postmenopausal women reported a 33% improvement in overall cognitive performance compared to placebo. The authors state that the review was not designed as a systematic review, that no formal meta-analysis, duplicate independent screening, or standardized risk-of-bias assessment was performed, and that the approach may therefore be subject to selection bias and may not capture all relevant studies.

  25. Return-to-work for people living with long COVID: A scoping review of interventions and recommendations.2025 · review
    Summary

    This scoping review asked which interventions may support return-to-work (RTW) or work ability in people living with Long COVID. The authors searched five electronic databases and grey literature up to January 3, 2025, and included 19 intervention studies and 12 clinical practice guidelines; study designs included cohort, quasi-experimental, observational, interventional, RCT and case-report designs. No comparison group was analysed. Interventions included multimodal and interdisciplinary work-focused rehabilitation, psychoeducation, pacing, breathing strategies, cognitive rehabilitation and workplace RTW planning, plus enhanced external counterpulsation, CICT and pulsed electromagnetic field therapy. Reported durations included a 3-day concentrated program, a 36-hour CICT intervention, and follow-up at six months and one-year. Findings varied: some studies reported improvement in workability, sick leave, fatigue, functional status, cognitive function or RTW; others reported no RTW improvement (Derksen et al. 2023), no significant overall RTW enhancement with physical conditioning (Hasenoehrl et al. 2023), 72% still unable to RTW after rehabilitation (Muller et al. 2023), and a 2% RTW improvement with a psychotherapy-based inpatient program (Kupferschmitt et al. 2023). The review states that graded exercise is contraindicated for people with PEM and that interventions ignoring PEM risk worsening fatigue.

  26. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  27. Cognitive dysfunction in post-COVID-19 condition: Mechanisms, management, and rehabilitation.2023 · review
    Summary

    This Review-Symposium addressed cognitive dysfunction in post-COVID-19 condition (PCC). It was not a randomised study and had no comparison group; enrolled, started and analysed patient numbers are not reported for the review itself. The review describes findings from other studies rather than its own cohort. Manera et al. reported that systemic steroids were associated with improved MMSE scores in a subgroup with COVID-19 and concurrent other infections. A recent preprint study reported that patients with acute COVID-19 who received nirmatrelvir were 26% less likely to develop PCC. In 64 patients with persistent symptoms after COVID-19, a 6-week interdisciplinary individualized pulmonary rehabilitation program was followed by improvement in 6-min walk distance and in the Fatigue Assessment Scale; In another study, a 12-week rehabilitation program was associated with a significant decrease in the proportion of patients reporting a cognitive deficit; the authors note both studies were observational without a control group. A case study reported measurable improvement of microcirculation in the eyes and general PCC symptoms after an aptamer directed to inactivate GPCR autoantibodies. A proof-of-concept study of computerized cognitive training demonstrated potential benefits. Harms reported include exercise increasing fatigue in ME/CFS and systemic exertion intolerance disease, and some patients experiencing severe fatigue and worsened symptoms with intensive cognitive interventions. The authors conclude that evidence specific to COVID-19-related cognitive impairments is limited.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime